...First of all, thank you for everyone here in person and those on the webcast for joining us today for our LUMRYZ Commercial Day. We really appreciate you taking a few hours out of your Thursday morning to come and listen to a lot of the insights that we've gathered and garnered over the last couple of years as we frame out the early launch period and how we think about this unique opportunity. So before we get started, I'll remind all of you and point your attention toward our -- all of our risk factors. We certainly may make some forward-looking statements here today and point you to our SEC filing of our 10-K for December 31, 2022, which was filed earlier this year and can be found on the Investors section of our website at www.avadel.com. So although this is really the LUMRYZ Commercial Day, it really is, in our view, an ushering of a new oxybate therapy. It's an opportunity to not only transform Avadel into a high-growth commercial stage company but also to transform the narcolepsy...
